Cargando…

The Host-Pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains

BACKGROUND: Cyclophilin A (CypA) represents a potential key molecule in future antiretroviral therapy since inhibition of CypA suppresses human immunodeficiency virus type 1 (HIV-1) replication. CypA interacts with the virus proteins Capsid (CA) and Vpr, however, the mechanism through which CypA inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Solbak, Sara MØ, Wray, Victor, Horvli, Ole, Raae, Arnt J, Flydal, Marte I, Henklein, Petra, Henklein, Peter, Nimtz, Manfred, Schubert, Ulrich, Fossen, Torgils
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269379/
https://www.ncbi.nlm.nih.gov/pubmed/22185200
http://dx.doi.org/10.1186/1472-6807-11-49
_version_ 1782222466823749632
author Solbak, Sara MØ
Wray, Victor
Horvli, Ole
Raae, Arnt J
Flydal, Marte I
Henklein, Petra
Henklein, Peter
Nimtz, Manfred
Schubert, Ulrich
Fossen, Torgils
author_facet Solbak, Sara MØ
Wray, Victor
Horvli, Ole
Raae, Arnt J
Flydal, Marte I
Henklein, Petra
Henklein, Peter
Nimtz, Manfred
Schubert, Ulrich
Fossen, Torgils
author_sort Solbak, Sara MØ
collection PubMed
description BACKGROUND: Cyclophilin A (CypA) represents a potential key molecule in future antiretroviral therapy since inhibition of CypA suppresses human immunodeficiency virus type 1 (HIV-1) replication. CypA interacts with the virus proteins Capsid (CA) and Vpr, however, the mechanism through which CypA influences HIV-1 infectivity still remains unclear. RESULTS: Here the interaction of full-length HIV-1 Vpr with the host cellular factor CypA has been characterized and quantified by surface plasmon resonance spectroscopy. A C-terminal region of Vpr, comprising the 16 residues (75)GCRHSRIGVTRQRRAR(90), with high binding affinity for CypA has been identified. This region of Vpr does not contain any proline residues but binds much more strongly to CypA than the previously characterized N-terminal binding domain of Vpr, and is thus the first protein binding domain to CypA described involving no proline residues. The fact that the mutant peptide Vpr(75-90 )R80A binds more weakly to CypA than the wild-type peptide confirms that Arg-80 is a key residue in the C-terminal binding domain. The N- and C-terminal binding regions of full-length Vpr bind cooperatively to CypA and have allowed a model of the complex to be created. The dissociation constant of full-length Vpr to CypA was determined to be approximately 320 nM, indicating that the binding may be stronger than that of the well characterized interaction of HIV-1 CA with CypA. CONCLUSIONS: For the first time the interaction of full-length Vpr and CypA has been characterized and quantified. A non-proline-containing 16-residue region of C-terminal Vpr which binds specifically to CypA with similar high affinity as full-length Vpr has been identified. The fact that this is the first non-proline containing binding motif of any protein found to bind to CypA, changes the view on how CypA is able to interact with other proteins. It is interesting to note that several previously reported key functions of HIV-1 Vpr are associated with the identified N- and C-terminal binding domains of the protein to CypA.
format Online
Article
Text
id pubmed-3269379
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32693792012-02-01 The Host-Pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains Solbak, Sara MØ Wray, Victor Horvli, Ole Raae, Arnt J Flydal, Marte I Henklein, Petra Henklein, Peter Nimtz, Manfred Schubert, Ulrich Fossen, Torgils BMC Struct Biol Research Article BACKGROUND: Cyclophilin A (CypA) represents a potential key molecule in future antiretroviral therapy since inhibition of CypA suppresses human immunodeficiency virus type 1 (HIV-1) replication. CypA interacts with the virus proteins Capsid (CA) and Vpr, however, the mechanism through which CypA influences HIV-1 infectivity still remains unclear. RESULTS: Here the interaction of full-length HIV-1 Vpr with the host cellular factor CypA has been characterized and quantified by surface plasmon resonance spectroscopy. A C-terminal region of Vpr, comprising the 16 residues (75)GCRHSRIGVTRQRRAR(90), with high binding affinity for CypA has been identified. This region of Vpr does not contain any proline residues but binds much more strongly to CypA than the previously characterized N-terminal binding domain of Vpr, and is thus the first protein binding domain to CypA described involving no proline residues. The fact that the mutant peptide Vpr(75-90 )R80A binds more weakly to CypA than the wild-type peptide confirms that Arg-80 is a key residue in the C-terminal binding domain. The N- and C-terminal binding regions of full-length Vpr bind cooperatively to CypA and have allowed a model of the complex to be created. The dissociation constant of full-length Vpr to CypA was determined to be approximately 320 nM, indicating that the binding may be stronger than that of the well characterized interaction of HIV-1 CA with CypA. CONCLUSIONS: For the first time the interaction of full-length Vpr and CypA has been characterized and quantified. A non-proline-containing 16-residue region of C-terminal Vpr which binds specifically to CypA with similar high affinity as full-length Vpr has been identified. The fact that this is the first non-proline containing binding motif of any protein found to bind to CypA, changes the view on how CypA is able to interact with other proteins. It is interesting to note that several previously reported key functions of HIV-1 Vpr are associated with the identified N- and C-terminal binding domains of the protein to CypA. BioMed Central 2011-12-20 /pmc/articles/PMC3269379/ /pubmed/22185200 http://dx.doi.org/10.1186/1472-6807-11-49 Text en Copyright ©2011 Solbak et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Solbak, Sara MØ
Wray, Victor
Horvli, Ole
Raae, Arnt J
Flydal, Marte I
Henklein, Petra
Henklein, Peter
Nimtz, Manfred
Schubert, Ulrich
Fossen, Torgils
The Host-Pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains
title The Host-Pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains
title_full The Host-Pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains
title_fullStr The Host-Pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains
title_full_unstemmed The Host-Pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains
title_short The Host-Pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains
title_sort host-pathogen interaction of human cyclophilin a and hiv-1 vpr requires specific n-terminal and novel c-terminal domains
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269379/
https://www.ncbi.nlm.nih.gov/pubmed/22185200
http://dx.doi.org/10.1186/1472-6807-11-49
work_keys_str_mv AT solbaksaramø thehostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT wrayvictor thehostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT horvliole thehostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT raaearntj thehostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT flydalmartei thehostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT henkleinpetra thehostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT henkleinpeter thehostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT nimtzmanfred thehostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT schubertulrich thehostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT fossentorgils thehostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT solbaksaramø hostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT wrayvictor hostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT horvliole hostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT raaearntj hostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT flydalmartei hostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT henkleinpetra hostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT henkleinpeter hostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT nimtzmanfred hostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT schubertulrich hostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains
AT fossentorgils hostpathogeninteractionofhumancyclophilinaandhiv1vprrequiresspecificnterminalandnovelcterminaldomains